Literature DB >> 9388028

Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin.

D R Brown1, J P Lloyd, J J Schmidt.   

Abstract

Clostridium botulinum may produce any of seven known serotypes of neurotoxin (BoNT/A-/G), which are the most toxic bacterial proteins known. Efforts to develop a second-generation vaccine to these toxins would benefit from the isolation of hybridomas producing neutralizing monoclonal antibodies (MAbs). We hypothesized that previous efforts to isolate neutralizing MAbs against various BoNTs failed due to use of toxoided, chemically altered antigens. We employed a novel vaccination regimen employing native, active, single-chain BoNT/E (scBoNT/E). A number of the BoNT/E immunized mice were further vaccinated with lethal doses of fully active BoNT/F. MAb 7F8 consistently neutralized BoNT/F in three different assays: in vivo neutralization, passive neutralization, and neutralization of regional paralysis. There was no detectable recognition and essentially no neutralization of scBoNT/E. The epitope recognized by this MAb was denatured when treated with formalin, urea, guanidine chloride, or sodium dodecyl sulfate. Preliminary epitope mapping studies indicate that the MAb bound to a conformational epitope.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9388028     DOI: 10.1089/hyb.1997.16.447

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  8 in total

1.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

3.  Epitope mapping of botulinum neurotoxins light chains.

Authors:  Alexey Zdanovsky; Denis Zdanovsky; Maria Zdanovskaia
Journal:  Toxicon       Date:  2012-08-14       Impact factor: 3.033

Review 4.  Monoclonal antibodies and toxins--a perspective on function and isotype.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Toxins (Basel)       Date:  2012-06-11       Impact factor: 4.546

Review 5.  The evolving field of biodefence: therapeutic developments and diagnostics.

Authors:  James C Burnett; Erik A Henchal; Alan L Schmaljohn; Sina Bavari
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

6.  Sheep monoclonal antibodies prevent systemic effects of botulinum neurotoxin A1.

Authors:  Jean Mukherjee; Chase McCann; Kwasi Ofori; Julia Hill; Karen Baldwin; Charles B Shoemaker; Peter Harrison; Saul Tzipori
Journal:  Toxins (Basel)       Date:  2012-12       Impact factor: 4.546

Review 7.  Passive antibody administration (immediate immunity) as a specific defense against biological weapons.

Authors:  Arturo Casadevall
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

8.  Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.

Authors:  Eran Diamant; Bat-El Lachmi; Adi Keren; Ada Barnea; Hadar Marcus; Shoshana Cohen; Alon Ben David; Ran Zichel
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.